{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:57:12Z","timestamp":1788587832976,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00978-0","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:08:35Z","timestamp":1781942915000},"page":"2073-2095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Observational Retrospective Cohort of Patient Support Program Data on Practical Experiences of Treatment with Foslevodopa\/Foscarbidopa in Advanced Parkinson\u2019s Disease: The ORCHESTRA Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Tobias","family":"Warnecke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton Adriaan","family":"Van der Plas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Schwingenschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Simu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resmi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"S\u00fcdmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"10423","key":"978_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","volume":"403","author":"Y Ben-Shlomo","year":"2024","unstructured":"Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C. The epidemiology of Parkinson\u2019s disease. The Lancet. 2024;403(10423):283\u201392.","journal-title":"The Lancet"},{"issue":"8","key":"978_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.nrl.2013.05.001","volume":"28","author":"J Kulisevsky","year":"2013","unstructured":"Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, et al. [Advanced Parkinson\u2019s disease: clinical characteristics and treatment (part 1)]. Neurologia. 2013;28(8):503\u201321.","journal-title":"Neurologia"},{"issue":"s1","key":"978_CR3","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-202104","volume":"10","author":"JM Dijk","year":"2020","unstructured":"Dijk JM, Espay AJ, Katzenschlager R, de Bie RMA. The choice between advanced therapies for parkinson\u2019s disease patients: why, what, and when? J Parkinsons Dis. 2020;10(s1):S65\u201373.","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"978_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3233\/JPD-202147","volume":"11","author":"N Dahodwala","year":"2021","unstructured":"Dahodwala N, Jahnke J, Pettit AR, Li P, Ladage VP, Kandukuri PL, et al. Low sustainment of high-dose oral medication regimens for advanced Parkinson\u2019s disease in medicare beneficiaries. J Parkinsons Dis. 2021;11(2):675\u201384.","journal-title":"J Parkinsons Dis"},{"key":"978_CR5","unstructured":"AbbVie Inc. Levodopa\/carbidopa intestinal gel: summary of product characteristics 2024. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/15213\/smpc."},{"key":"978_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.107293","volume":"132","author":"AL Ellenbogen","year":"2025","unstructured":"Ellenbogen AL, Poewe W, Espay AJ, Simuni T, Gurevich T, Yardeni T, et al. Long-term, continuous, subcutaneous levodopa\/carbidopa infusion with ND0612 in Parkinson\u2019s disease: 3-year outcomes from the open-label BeyoND study. Parkinsonism Relat Disord. 2025;132:107293.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"978_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1474-4422(24)00052-8","volume":"23","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, et al. Safety and efficacy of continuous subcutaneous levodopa\u2013carbidopa infusion (ND0612) for Parkinson\u2019s disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol. 2024;23(5):465\u201376.","journal-title":"Lancet Neurol"},{"issue":"9","key":"978_CR8","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet Neurology. 2018;17(9):749\u201359.","journal-title":"The Lancet Neurology"},{"issue":"6","key":"978_CR9","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, et al. Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther. 2023;12(6):1937\u201358.","journal-title":"Neurol Ther"},{"issue":"12","key":"978_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022;21(12):1099\u2013109.","journal-title":"Lancet Neurol"},{"issue":"4","key":"978_CR11","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3233\/JPD-212813","volume":"11","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh M, Liu W, Neenan M, Facheris MF. Foslevodopa\/foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion. J Parkinsons Dis. 2021;11(4):1695\u2013702.","journal-title":"J Parkinsons Dis"},{"key":"978_CR12","doi-asserted-by":"crossref","unstructured":"Jost WH, Bergquist F, Evans A, Hassin-Baer S, Hauser R, Henriksen T, et al. Real-world safety and effectiveness of foslevodopa\/foscarbidopa in Parkinson\u2019s disease: ROSSINI study 6-month interim results [Late Breaker]. Movement Disorder Society 2025 Annual Meeting; Honolulu, HI2025.","DOI":"10.1007\/s40120-026-00948-6"},{"key":"978_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jnc.13750","volume":"139","author":"W Oertel","year":"2016","unstructured":"Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem. 2016;139:325\u201337.","journal-title":"J Neurochem"},{"key":"978_CR14","doi-asserted-by":"publisher","first-page":"1619850","DOI":"10.3389\/fnagi.2025.1619850","volume":"17","author":"A Jander","year":"2025","unstructured":"Jander A, Bergner S, Schonwald B, Potter-Nerger M, Buhmann C, Hidding U. Subcutaneous foslevodopa\/foscarbidopa initiation in a Parkinson\u2019s day-clinic\u2014a suitable setting to ensure treatment efficacy, tolerability and psychosocial adaption. Front Aging Neurosci. 2025;17:1619850.","journal-title":"Front Aging Neurosci"},{"issue":"12","key":"978_CR15","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/mdc3.70249","volume":"12","author":"K Rukavina","year":"2025","unstructured":"Rukavina K, Ebersbach G, Gruber D. Foslevodopa\/foscarbidopa continuous subcutaneous infusion in Parkinson\u2019s disease: real-world short-term data on tolerability, infusion rate adjustments and concomitant medication. Mov Disord Clin Pract. 2025;12(12):2317\u201323.","journal-title":"Mov Disord Clin Pract"},{"key":"978_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2024.100239","volume":"10","author":"VS Fung","year":"2024","unstructured":"Fung VS, Aldred J, Arroyo MP, Bergquist F, Boon AJ, Bouchard M, et al. Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson\u2019s disease: considerations for initiation and maintenance. Clin Parkinsonism Related Disord. 2024;10:100239.","journal-title":"Clin Parkinsonism Related Disord"},{"key":"978_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.107896","volume":"136","author":"N Nishikawa","year":"2025","unstructured":"Nishikawa N, Hatano T, Kamiyama D, Kamo H, Oji Y, Abe C, et al. Predictors of discontinuation in foslevodopa\/foscarbidopa therapy for Parkinson\u2019s disease. Parkinsonism Relat Disord. 2025;136:107896.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"978_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40120-025-00856-1","volume":"15","author":"A Antonini","year":"2026","unstructured":"Antonini A, Bergmans B, Kern DS, Gandor F, Nishikawa N, Standaert DG, et al. Foslevodopa\/foscarbidopa in younger patients earlier within advanced Parkinson\u2019s disease: post hoc analysis of a randomized trial. Neurol Ther. 2026;15(1):309\u201324.","journal-title":"Neurol Ther"},{"key":"978_CR19","doi-asserted-by":"crossref","unstructured":"Chaudhuri KR, Bergmans B, Freire-Alvarez E, Hopes L, Kern DS, Kirsner RS, et al. Considerations for Initiation and Maintenance of Foslevodopa\/Foscarbidopa for Advanced Parkinson's Disease. Mov Disord Clin Pract. 2026.","DOI":"10.1002\/mdc3.70489"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00978-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00978-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00978-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:39Z","timestamp":1784819499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00978-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["978"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00978-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Martin S\u00fcdmeyer reports receiving consulting fees and lecture fees from Abbott, Boston Scientific, Lilly, AbbVie, Medtronic, Zambon, Stadapharma, UCB, and Desitin. Tobias Warnecke has received: Honoraria for advisory boards (AbbVie, Archimedes, Phagenesis, Zambon, Bial, Kyowa, STADA, Britannia, Merz, UCB, Mitsubishi Tanabe), Honoraria for lectures (Esteve, Britannia, Bial, AbbVie, STADA, UCB, Biogen, Licher, Desitin, Pfizer, Zambon, Teva, Bayer, Ever Pharma, Merz, Neuraxpharm, Esteve); Grants (investigator-initiated) (Licher, AbbVie, Clexio, UCB); Academic grants (G-BA Innovation Fund, Deutsche Parkinson-Vereinigung (dPV), IZKF, Neuro NRW). Anton Adriaan van der Plas has received: Honoraria for advisory boards: AbbVie, Britannia. Anders Johansson has served as an investigator in clinical trials sponsored by AbbVie, BIAL, Integrative Research Laboratories and Neurolixis, and his institution has received honoraria from AbbVie for his educational presentations. Petra Schwingenschuh reports receiving consulting fees and lecture fees from AbbVie, Bial, Merz, and\u00a0Stadapharma. Mihaela Simu has received honoraria for lectures at symposia and consultant fees from AbbVie, AOP Orphan, Boehringer Ingelheim, Krka, Merck, Novartis, Roche, Sanofi, Servier, Teva, and UCB. Marie O\u2019Meara, Resmi Gupta, Bjoern Fritz, Lars Bergmann, and Juan Carlos Parra are full-time employees of AbbVie and may hold AbbVie stock and\/or stock options.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the protocol and utilized a framework for conducting compliant secondary scientific research using data collected through a Patient Support Program\n                      .\n                      The study protocol and recruitment materials were approved by independent ethics committees or institutional review boards in Germany (reference number: Bo\/20\/2025-Studie-01), Sweden (reference number: 2025\u201302176-01), Austria (reference number: 1127\/2025\n                      )\n                      , and Romania (reference number: 7SNI\/9Apr2025). Ethics approval was not required in the Netherlands. This study used de-identified patient data for compatible scientific research and publication purposes; this use is captured in the patient consent and privacy notice on enrollment into the PSP and additional patient consent was not required for the purposes of the study.","order":2,"name":"Ethics","label":"Ethics\/Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}